Abstract: The present invention relates to a crystal form of a sphingosine-1-phosphate receptor agonist and, more specifically, to 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazole-5-ylmethoxy)-3,4-dihydro-naphthalene-2-ylmethyl]-piperidine-4-carboxylic acid of chemical formula 1, or a crystal form of a solvate or a pharmaceutically acceptable salt thereof.
| # | Name | Date |
|---|---|---|
| 1 | 202317077144-STATEMENT OF UNDERTAKING (FORM 3) [11-11-2023(online)].pdf | 2023-11-11 |
| 2 | 202317077144-REQUEST FOR EXAMINATION (FORM-18) [11-11-2023(online)].pdf | 2023-11-11 |
| 3 | 202317077144-PRIORITY DOCUMENTS [11-11-2023(online)].pdf | 2023-11-11 |
| 4 | 202317077144-POWER OF AUTHORITY [11-11-2023(online)].pdf | 2023-11-11 |
| 5 | 202317077144-FORM 18 [11-11-2023(online)].pdf | 2023-11-11 |
| 6 | 202317077144-FORM 1 [11-11-2023(online)].pdf | 2023-11-11 |
| 7 | 202317077144-DRAWINGS [11-11-2023(online)].pdf | 2023-11-11 |
| 8 | 202317077144-DECLARATION OF INVENTORSHIP (FORM 5) [11-11-2023(online)].pdf | 2023-11-11 |
| 9 | 202317077144-COMPLETE SPECIFICATION [11-11-2023(online)].pdf | 2023-11-11 |
| 10 | 202317077144-Proof of Right [07-05-2024(online)].pdf | 2024-05-07 |
| 11 | 202317077144-FORM 3 [07-05-2024(online)].pdf | 2024-05-07 |